Anti-tumor efficacy of a therapeutic peptide based on thermo-responsive elastin-like polypeptide in combination with gemcitabine
Authors:
- 1 June 2014
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 348 (1-2) , 177-184
Abstract
No abstract availableKeywords
Funding Information
- National Science Foundation-United States (CBET-0931041)
- National Cancer Institute-United States (R21CA113813-01A)
This publication has 23 references indexed in Scilit:
- Thermally Targeted Delivery of a c-Myc Inhibitory Polypeptide Inhibits Tumor Progression and Extends Survival in a Rat Glioma ModelPLOS ONE, 2013
- Thermal Targeting of an Acid-Sensitive Doxorubicin Conjugate of Elastin-like Polypeptide Enhances the Therapeutic Efficacy Compared with the Parent CompoundIn VivoMolecular Cancer Therapeutics, 2012
- A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growthCancer Letters, 2012
- Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical applicationTrends in Biotechnology, 2010
- Inhibition of ovarian cancer cell proliferation by a cell cycle inhibitory peptide fused to a thermally responsive polypeptide carrierInternational Journal of Cancer, 2009
- Inhibition of ovarian cancer cell metastasis by a fusion polypeptide Tat-ELPClinical & Experimental Metastasis, 2009
- A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistanceInvestigational New Drugs, 2007
- Development of elastin-like polypeptide for thermally targeted delivery of doxorubicinBiochemical Pharmacology, 2007
- Evaluation of an elastin-like polypeptide–doxorubicin conjugate for cancer therapyJournal of Controlled Release, 2003
- Targeted drug delivery by thermally responsive polymersAdvanced Drug Delivery Reviews, 2002